Literature DB >> 31229727

Bioremoval of non-steroidal anti-inflammatory drugs by Pseudoxanthomonas sp. DIN-3 isolated from biological activated carbon process.

Zedong Lu1, Wenjun Sun2, Chen Li1, Xiuwei Ao1, Chao Yang1, Simiao Li1.   

Abstract

The presence of non-steroidal anti-inflammatory drugs (NSAIDs) in the environment is an emerging concern owing to their potential threat on aquatic ecosystems and living organisms. To investigate the bioremoval potential of a biological activated carbon (BAC) filter for the removal of NSAIDs, removal of diclofenac (DCF), ibuprofen (IBU), and naproxen (NAP) by biofilms on a bench-scaled BAC column operated for 400 days was studied. The results showed that the BAC column effectively removed the three NSAIDs (>90%). One bacterial strain isolated from the BAC, Pseudoxanthomonas sp. DIN-3, was able to simultaneously remove DCF, IBU, and NAP, which were supplied as the sole carbon source. In 14 days, 23%, 41%, and 39% of DCF, IBU, and NAP (50 μg L-1) were bioremoved, respectively, and strain DIN-3 eliminated IBU more rapidly than the other two NSAIDs. If only a single drug was added as the sole carbon source, ignoring the other drugs, the removal ability was overestimated by 5.0-27.0%. More efficient bioremoval was achieved, concomitantly with bacterial growth, via a co-metabolism with acetate, glucose, or methanol. Their intermediates were identified by UPLC-QQQ-MS, and their respective degradation pathways were also proposed. Moreover, based on the complete genome sequence of strain DIN-3, 49 related genes encoding the main enzymes involved in DCF, IBU, and NAP biodegradation were identified, including hemE, lpd, yihx, ligC, pobA, and ligA. These results suggested that Pseudoxanthomonas sp. DIN-3 is a potential degrader of DCF, IBU, and NAP, and to the best of our knowledge, this is the first report that demonstrates the bioremoval of DCF, IBU, and NAP simultaneously by an individual bacterial strain isolated from the environment. However, the bioremoval potential should be evaluated when assessing the applicability of the strain in the environment because of the combined effects of various pharmaceutical contaminants. The obtained results provide a foundation for the use of Pseudoxanthomonas sp. DIN-3 in the bioremoval of polycyclic NSAID-contaminated environments.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biological activated carbon; Bioremoval; Combination effects; Non-steroidal anti-inflammatory drugs (NSAIDs); Pseudoxanthomonas sp. DIN-3

Mesh:

Substances:

Year:  2019        PMID: 31229727     DOI: 10.1016/j.watres.2019.05.065

Source DB:  PubMed          Journal:  Water Res        ISSN: 0043-1354            Impact factor:   11.236


  4 in total

1.  Utilization of naproxen by Amycolatopsis sp. Poz 14 and detection of the enzymes involved in the degradation metabolic pathway.

Authors:  B M Alanis-Sánchez; S M Pérez-Tapia; S Vázquez-Leyva; I Mejía-Calvo; Z Macías-Palacios; L Vallejo-Castillo; C M Flores-Ortiz; C Guerrero-Barajas; J A Cruz-Maya; J Jan-Roblero
Journal:  World J Microbiol Biotechnol       Date:  2019-11-14       Impact factor: 3.312

2.  Anaerobic 1,4-dioxane biodegradation and microbial community analysis in microcosms inoculated with soils or sediments and different electron acceptors.

Authors:  Vidhya Ramalingam; Alison M Cupples
Journal:  Appl Microbiol Biotechnol       Date:  2020-03-13       Impact factor: 4.813

3.  A Correlation Study of the Microbiota Between Oral Cavity and Tonsils in Children With Tonsillar Hypertrophy.

Authors:  He Xu; Bijun Tian; Weihua Shi; Jing Tian; Xuexi Zhang; Jin Zeng; Man Qin
Journal:  Front Cell Infect Microbiol       Date:  2022-01-28       Impact factor: 5.293

4.  Microaerobic enrichment of benzene-degrading bacteria and description of Ideonella benzenivorans sp. nov., capable of degrading benzene, toluene and ethylbenzene under microaerobic conditions.

Authors:  Anna Bedics; András Táncsics; Erika Tóth; Sinchan Banerjee; Péter Harkai; Balázs Kovács; Károly Bóka; Balázs Kriszt
Journal:  Antonie Van Leeuwenhoek       Date:  2022-07-16       Impact factor: 2.158

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.